Boston Children's Hospital at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Boston Children's Hospital brings 5 presentations to ESGCT 2026 in Hamburg. Its work spans long-term outcomes after gene therapy and new ways to deliver editors, including virus-like particles carrying Cas9. Other strands cover tailored base and prime editing for a rare inflammatory disease and vectors that generate CAR T cells in the body.
| Organization | ESGCT 2026 Attendance |
|---|---|
Boston Children's Hospital Boston, Massachusetts | |
Paediatric teaching hospital of Harvard Medical School with a gene therapy program running trials in blood, immune and neurological disorders. | Workshop Tue Oct 27 11:15am–1:00pm Long-term effects of gene therapy Clinical trials and translation Poster Wed Oct 28 1:30pm–3:30pm Optimized Lentivirus-Derived Virus-Like Particles for Efficient Delivery of Cas9-Based Genome Editors Chair Wed Oct 28 3:30pm–5:30pm SESSION 5: In vivo gene therapy Vectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Alpha-retroviral vectors enable in vivo generation of ALK-targeted CAR-T cells in a metastatic neuroblastoma model Poster Thu Oct 29 2:00pm–4:00pm Bespoke base and prime editing strategies to treat STING-associated vascolupathy with onset in infancy (SAVI) Talk Thu Oct 29 6:30pm–7:30pm Leveraging viral vectors from bench to clinic Vectors and delivery (AAV, lentiviral, LNP)Clinical trials and translation |
Instantly find 20 buyers from Boston Children's Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction